Cryoablation, the destruction of malignant cancer cells by freezing them, is increasingly becoming an alternative to having ...

IceCure Medical (ICCM) announced that interim results from the Company’s ICESECRET study of cryoablation for patients with small renal masses ...

A recent study suggests that using artificial intelligence to measure tumor size could reduce treatment failures by more than 70%.

The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment ...

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most ...

“Our resources are now focused on the completion of the FULCRUM-VT Pivotal IDE trial and subsequent premarket approval of the VT Cryoablation System with vCLAS™ catheter from the U.S. Food and Drug ...

IceCure Medical has sought approval from Israel's Ministry of Health’s Medical Device Division (AMAR) for its XSense cryoablation system and cryoprobes. Both components have already gained ...

CAESAREA, Israel, March 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...